Project Grant R01NS153446
- The National Institute of Neurological Disorders and Stroke, part of the Department of Health and Human Services National Institutes of Health, awarded $544,568 to Cleveland Clinic Lerner College of Medicine of Case Western Reserve University on February 11, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to investigate the pathogenesis of permanent neurological disability in multiple sclerosis. The research identifies cellular...
- The National Institute of Neurological Disorders and Stroke awarded the University of Massachusetts Medical School $551,557 on August 15, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to investigate nucleic acid sensing pathways in demyelinating disease. The funded research dissects the role of endosomal toll-like receptors (eTLRs) in neuroinflammation and demyelination, specifically examining how aberrant eTLR signaling in...
- The National Institute of Neurological Disorders and Stroke, an operating division of the Department of Health and Human Services National Institutes of Health, awarded The Ohio State University $611,634 on May 15, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to investigate age-associated expansion of natural IgM FCRL5+ B cell clones as drivers of progressive multiple sclerosis and potential therapeutic targets. The research...
- The National Institute of Neurological Disorders and Stroke awarded the University of Illinois $400,825 on May 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to support research into the mechanisms and rescue of axonal degeneration in hereditary spastic paraplegia neurons. The award funds investigation of how mutations in the SPG11 and ZFYVE26 genes—which cause two common forms of hereditary spastic paraplegia (HSP)—lead to...
- The National Institute of Neurological Disorders and Stroke awarded Northwestern University $509,949 on August 21, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to support basic research elucidating mechanisms of chromosomal organization in control of neuronal connectivity in the brain. The funded research investigates mega-enhancer bodies (ME bodies) that compartmentalize neuronal long genes encoding synaptic proteins within...
- The National Institute of Neurological Disorders and Stroke awarded The University of Iowa $231,350 on February 5, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to elucidate learning-induced molecular signatures in hippocampal mature oligodendrocytes at single-cell and spatial resolution. The research investigates how mature oligodendrocytes regulate hippocampal function during memory consolidation. While mature...
- The National Institute of Neurological Disorders and Stroke awarded The Washington University $618,001 on September 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to develop and validate deuterium metabolic spectroscopy and imaging (DMS/I) as a technique for non-invasively measuring brain glucose and ketone metabolism in multiple sclerosis. The project uses deuterium-labeled metabolic tracers to investigate how energy...
- The National Institute of Neurological Disorders and Stroke awarded the Sloan-Kettering Institute for Cancer Research $484,000 on May 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The award funds research characterizing and inhibiting interactions of the alpha-secretase ADAM17 with the neuronal-myelin signaling complex upon spinal cord injury. The study investigates how myelin-associated inhibitors—including...
- The National Institute of Neurological Disorders and Stroke awarded The Trustees of Columbia University in the City of New York $126,900 on March 7, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The award funds research to exploit RNA biogenesis, specifically alternative splicing programs, to accelerate maturation of human neurons in vitro and to develop models of age-related tauopathies. The research addresses a fundamental...
- The National Institute of Neurological Disorders and Stroke awarded New York University $247,300 on July 14, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to develop quantitative MRI methods for assessing white matter injury and repair. The project integrates multi-shell, multi-diffusion time MRI with large-scale three-dimensional electron microscopy and quantitative immunofluorescence to establish how diffusion and T2-based...
The National Institute of Neurological Disorders and Stroke awarded the University of Illinois $407,211 on August 21, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to conduct research on neural progenitor cell differentiation and therapeutic mechanisms in multiple sclerosis. The research investigates a natural product-derived Notch1 signaling inhibitor, (+)-3D-spiro-oxindole, designed to promote neural progenitor and stem cell differentiation into neurons and oligodendrocytes while suppressing neuroinflammation in central nervous system lesions. Preliminary studies demonstrated that the compound markedly improved motor dysfunction, enhanced motor neuron regeneration, promoted remyelination, and reduced neuroinflammation in the spinal cords of experimental autoimmune encephalomyelitis mice. The project addresses three specific aims: determining the mechanisms of neurogenesis and oligodendrogenesis induced by (+)-3D-spiro-oxindole in human neural progenitor cells by targeting its binding partner, CYB5R3; defining the neurogenic and oligodendrogenic potential of the compound in multiple mouse models of multiple sclerosis; and elucidating how endogenous neural progenitor cell upregulation can be harnessed therapeutically. Performance takes place in Urbana, Illinois, with a period of performance from August 21, 2026, through May 31, 2031. This is a Project Grant, the standard assistance type for NIH extramural research.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $407.2k | 8/21/26 |